SCHEMBL10276545

SCHEMBL10276545

Cc1ccc(-c2ccc(F)cc2F)cc2[nH]c(-c3ccc(N)cc3)cc(=O)n2[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
KDM4E B2RXH2 4/20 0.39
HPGD P15428 4/20 0.39
HSD17B10 Q99714 3/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
TDP2 O95551 1/20 0.35
GCGR P47871 1/20 0.34
MAPK14 Q16539 1/20 0.34
THRB P10828 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
KLKB1 P03952 1/20 0.33
DHODH Q02127 1/20 0.33
TP53 P04637 3/20 0.33
KIT P10721 2/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10275827 0.88 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL10275912 0.74 GCGR (0.36) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL10276239 0.73 PDE3B (0.33) TDP2MAPK14PDE3BPDE3A
SCHEMBL10276014 0.70 PGR (0.38) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL11545227 0.67 TAAR1 (0.50) ALDH1A1KDM4EHPGDHSD17B10MEN1
SCHEMBL2637446 0.62 RAD51 (0.43) ALDH1A1KDM4ERAB9ASMN1; SMN2RAD51
SCHEMBL25212486 0.61 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL12825455 0.59 CYP1A1 (0.53) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL20772691 0.59 KDM4E (0.50) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL30832866 0.59 KDM4E (0.50) ALDH1A1KDM4EHPGDHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 ALDH1A1 572/4885KDM4E 3483/4885HPGD 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.